Article
The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance.
PloS one - 1 Jan 2021
Bobardt Michael, Ramirez Christina M, Baum Marc M, Ure Daren, Foster Robert, Gallay Philippe A
Abstract excerpt
We and others previously reported that the direct-acting agents (DAA) NS5A inhibitors (NS5Ai) and the host-targeting agents cyclophilin inhibitors (CypIs) inhibit HCV replication in vitro. In this study, we investigated whether the combination of NS5Ai and CypI offers a potent anti-HCV effect in vivo. A single administration of NS5Ai or CypI alone to HCV-infected humanized-mice inhibits HCV replication. The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.